Klaus P. Hoeflich

11.8k citations
69 papers · 9.7k · 3 hit papers · h-index 43

Impact in

  • Oncology top 1%
    • HER2/EGFR in Cancer Research
    • Cancer-related Molecular Pathways
    • Melanoma and MAPK Pathways
    • Protein Kinase Regulation and GTPase Signaling
    • PI3K/AKT/mTOR signaling in cancer
    • Wnt/β-catenin signaling in development and cancer

Papers in

    • Cancer-related Molecular Pathways 13
    • Peptidase Inhibition and Analysis 6
    • Melanoma and MAPK Pathways 21
    • Protein Kinase Regulation and GTPase Signaling 12
    • PI3K/AKT/mTOR signaling in cancer 8

Klaus P. Hoeflich

68 papers receiving 9.4k citations

Klaus P. Hoeflich's Hit Papers

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth 2010 · 1.4k citations
1.4k0+8+17Years since publication4008001.2k

Peers

Klaus P. Hoeflich
Comparison fields: 5 of 128
  • Oncology 2.8k
  • Molecular Biology 6.7k
  • Cancer Research 930
  • Cell Biology 767
  • Pathology and Forensic Medicine 706
Replace Alex N Bullock with:
Alex N Bullock United Kingdom
Loren D. Walensky United States
Brion William Murray United States
Adrian Mario Senderowicz United States
Florian Gnad Germany
Scott B. Ficarro United States
Rakesh Kumar United States
Stephen E. Fawell United States
Mikihiko Naito Japan
Jin Quan Cheng United States
Klaus P. Hoeflich relative to Alex N Bullock United Kingdom Alex N Bullock's profile →
Citations per field
00.5×1.5×
Alex N Bullock · 1×
Citations per year

Countries citing papers authored by Klaus P. Hoeflich

Since Specialization
Citations

This map shows the geographic impact of Klaus P. Hoeflich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus P. Hoeflich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus P. Hoeflich more than expected).

Fields of papers citing papers by Klaus P. Hoeflich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus P. Hoeflich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus P. Hoeflich. The network helps show where Klaus P. Hoeflich may publish in the future.

Co-authors

The 25 scholars most cited alongside Klaus P. Hoeflich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Klaus P. Hoeflich Line = papers co-authored together Klaus P. Hoeflich links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#Work
1
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hit paper breakdown →
20101369
2
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hit paper breakdown →
20001255
3 2002617
4
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Hit paper breakdown →
2008547
5 2003487
6 2009412
7 2015375
8 2008364
9 2001347
10 2013262
11 2009226
12 2011220
13 2019218
14 2006192
15 2012183
16 2011182
17 2009158
18 2009109
19 1999106
20 2012105

About Klaus P. Hoeflich

Klaus P. Hoeflich is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Cancer Research and Cell Biology, having authored 69 papers that have together received 9.7k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (21 papers), Cancer-related Molecular Pathways (13 papers), Protein Kinase Regulation and GTPase Signaling (12 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer Mechanisms and Therapy (6 papers), Peptidase Inhibition and Analysis (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Computational Drug Discovery Methods (5 papers). The work is most often cited by research in Oncology (2.8k citations), Molecular Biology (6.7k citations), Cancer Research (930 citations), Cell Biology (767 citations) and Pathology and Forensic Medicine (706 citations). Klaus P. Hoeflich has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Mitsuhiko Ikura, James Robert Woodgett, Ou Jin, Elizabeth A. Rubie, Ming‐Sound Tsao, Juan Luo, Lori Sickels Friedman, Howard Marvin Stern, Marcia P. Belvin and Adnan Hussein Ali. Their work appears in journals such as Cancer Research, Cancer Discovery, Journal of Medicinal Chemistry, Molecular Cancer Therapeutics and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact